VOR BIOPHARMA INC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs applyAbout VOR
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidates include tremtelectogene empogeditemcel (trem-cel), for the treatment of acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II multicenter, open-label, first-in-human study of trem-cel in patients with AML. Its other clinical trial and pipeline products are VCAR33 / VBP301, Trem-cel+VCAR33 Treatment, System CD33-CLL1 Treatment System, and VADC45.
Find out what a historical investment in VOR BIOPHARMA INC would be worth today using our VOR stock calculator.
$26.74M
-
0.00%
6.1M
$0.28
$0.21
$0.22
$1.80
$0.13
Ready to start your investing journey with Stake?
Open an accountVOR FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in VOR
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in VOR
on Stake
Buy VOR from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of VOR from only US$10 with fractional shares
